Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy

AIDS Research and Human Retroviruses

Volumn 29, Issue 10, 2013, Pages 1287-1292

  Eley, Timothy ^a   Huang, Shu Pang ^a   Conradie, Francesca ^b   Zorrilla, Carmen D ^c   Josipovic, Deirdre ^d   Botes, Mariëtte ^e   Osiyemi, Olayemi ^f   Hardy, Hélène ^a   Bertz, Richard ^a   McGrath, Donnie ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Scion Clinical Research   (South Africa)

^f Triple O Medical Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MATERNAL BLOOD; NEONATAL HYPERBILIRUBINEMIA; NEWBORN; PHARMACOGENETICS; PREGNANT WOMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

ADULT; ANTI-HIV AGENTS; BILIRUBIN; FEMALE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HUMANS; HYPERBILIRUBINEMIA; INFANT, NEWBORN; OLIGOPEPTIDES; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR;

EID: 84885088972     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0002     Document Type: Article

References (19)

1. Croom K, Dhillon S, and Keam S: Atazanavir. A review of its use in the management of HIV-1 infection. Drugs 2009;69(8):1107-1140.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services, October 14, 2011; 1-167.
3. Reyataz- (atazanavir sulfate) Prescribing Information (Revised March 2012). Available at http://packageinserts.bms .com/pi/pi-reyataz.pdf (accessed July 2013). 4. Conradie F, et al.: Safety and exposure of once-daily ritonavir- boosted atazanavir in HIV-infected pregnant women. HIV Med 2011;12(9):570-579.
4. Conradie F, et al.: Safety and exposure of once-daily ritonavir- boosted atazanavir in HIV-infected pregnant women. HIV Med 2011;12(9):570-579.
5. Hardy H, et al.: The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: Results of study AI424182 [poster 018]. In 1st International Workshop on HIV and Women, January 10-11, 2011.
6. Porter ML and Dennis BL: Hyperbilirubinemia in the term newborn. Am Fam Physician 2002;65(4):599-606.
7. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011; pp. 1-207. 28 February 2012; available from http://aidsinfo.nih.gov/contentfiles/ PerinatalGL.pdf (accessed July 2013). 8. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114(1):297-316.
8. Molina JM, et al.: Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53(3):323-332.
9. Molina JM, et al.: Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53(3):323-332.
10. Watson RL: Hyperbilirubinemia. Crit Care Nursing Clin N Am 2009;21(1):97-120.
11. Rodriguez No'voa S, et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42(2):291-295.
12. Turatti L, et al.: UGT1A1 28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazil. AIDS Res Hum Retroviruses 2012;28(9):815-818.
13. Mandelbrot L, et al.: Atazanavir in pregnancy: Impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol 2011;157(1):18-21.
14. Mirochnick M, et al.: Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011;56(5):412-419.
15. Mao Q: BCRP/ABCG2 in the placenta: Expression, function and regulation. Pharm Res 2008;25(6):1484.
16. Blazquez AG, et al.: Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol 2012;81(2):273-283.
17. Marin JJ, et al.: Molecular bases of the fetal liver-placentamaternal liver excretory pathway for cholephilic compounds. Liver Int 2008;28(4):435-454. (Pubitemid 351411130)
18. Ripamonti D, et al.: Atazanavir plus low-dose ritonavir in pregnancy: Pharmacokinetics and placental transfer. AIDS 2007;21(18):2409-2415. (Pubitemid 350145172)
19. Atkinson LR, et al.: Phototherapy use in jaundiced newborns in a large managed care organization: Do clinicians adhere to the guideline Pediatrics 2003;111(5 Pt 1):e555-561.